UNSPSC 51191573: Amiloride hydrochloride anhydrous

This classification denotes the anhydrous form of a potassium-sparing diuretic and intercalating agent with the molecular formula C6H8ClN7O.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZJ37245UC, chemically known as pyrazinecarboxamide, n-amidino-3,5-diamino-6-chloro-, monohydrochloride but more generally known as amiloride hydrochloride, which bears US NIH Compound Identifier 16230.

European Medicines Agency schedules Amiloride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00445MIG. Most nations, for tariff and trade purposes, schedule amiloride hydrochloride anhydrous under HS 29339990. As of Q4 2014, AMILORIDE HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. SMILES: C1(C(NC(C(N1)CL)N)N)C(=O)NC(=N)N.CL.

UNSPSC 51191573 Amiloride hydrochloride anhydrous is a Commodity code representing specific pharmaceutical and chemical active ingredients procured by state and local government health systems, water treatment facilities, and cooperative purchasing alliances. The recent solicitation activity under this code shows minimal direct alignment; the City of Meriden's bid (B027-15) for sodium bisulfite chemical supply targets water pollution control operations rather than pharmaceutical procurement, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP addresses generic multi-source pharmaceuticals and OTC products distributed across participating state and local health facilities. When state and local bodies source amiloride hydrochloride anhydrous or closely related diuretic agents, purchasing typically flows through cooperative pharmaceutical-supply contracts managed by health departments, state medicaid programs, county health systems, and regional purchasing alliances rather than through direct commodity buys. Issuing bodies for pharmaceutical-grade active ingredients and finished products span state health departments, Medicaid agencies, county health systems, municipal health facilities, and multi-state cooperative purchasing vehicles such as MMCAP.

Geographic spread of pharmaceutical-supply procurement involving amiloride and related active ingredients is nationwide, with cooperative purchasing agreements covering multiple states simultaneously — MMCAP's RFP, for instance, covers Minnesota and Oregon participants with wholesaler distribution through AmerisourceBergen (Cencara), Cardinal Health, and Morris & Dickson. The MMCAP RFP (posted January 20, 2026, due March 26, 2026) represents the most recent relevant opportunity in the source block, requiring manufacturers to provide comprehensive pricing for generic pharmaceuticals including specific National Drug Codes, with awarded vendors effective July 1, 2026. Proposals are evaluated 75 percent on price competitiveness, with remaining weight on fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain commercial general liability of $5,000,000, network security and privacy liability of $2,000,000, comply with cGMP and DSCSA, and hold contractual relationships with at least two of three authorized wholesalers. The City of Meriden opportunity (B027-15) is tangential to amiloride procurement and involves water-treatment chemical supply rather than pharmaceutical active ingredients.